CYV — Ceryvyn Therapeutics Share Price
Last trade - 00:00- AU$15.05m
- -AU$14.97m
- AU$0.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.51 | ||
| Price to Tang. Book | 0.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 15,047.76 | ||
| EV to EBITDA | -0.04 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1115.1% | ||
| Return on Equity | n/a | ||
| Operating Margin | 33023600% | ||
Financial Summary
| Year End 30th Jun | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.13 | 0.16 | 0.19 | 0.23 | 0 | 0.29 | 0.2 | -59.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ceryvyn Therapeutics Limited, formerly Opthea Limited, is an Australia-based clinical-stage biopharmaceutical company. The Company is focusing on developing therapies by translating advances in human biology into transformative medicines for patients with serious diseases. It focuses on identifying biological mechanisms that drive disease and developing targeted therapies capable of addressing unmet medical needs. Its focus is lymphangioleiomyomatosis (LAM), a rare, chronic and progressive systemic disease that predominantly affects women and primarily involves the lungs, where it leads to progressive loss of lung function. The Company's lead development program, CYV-101, is a fusion protein designed to selectively bind and neutralize VEGF-C and VEGF-D, key signaling proteins involved in pathological lymphangiogenesis. It targets a fundamental biological pathway to drive disease progression, CYV-101 offers a differentiated therapeutic approach for patients with LAM.
Directors
- Jeremy Levin NEC (68)
- Megan Baldwin CEO
- Karen Adams VFN
- Richard Chadwick OTH
- Mike Gerometta OTH
- Annette Leahy OTH
- Ian Leitch OTH
- Clare Price OTH
- Judith Robertson OTH (61)
- Lawrence Gozlan NID
- Julia Haller NID (66)
- Michael Sistenich NID
- Daniel Spiegelman NID (62)
- Last Annual
- June 30th, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- October 17th, 1984
- Public Since
- April 9th, 1985
- No. of Shareholders
- 7,940
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,367,978,173
- Address
- Suite 1, Level 1, 117 Camberwell Road, H, 3123
- Web
- https://opthea.com/
- Phone
- +61 null398260399
- Auditors
- Deloitte
Latest News for CYV
Upcoming Events for CYV
Ceryvyn Therapeutics Ltd Annual Shareholders Meeting
Half Year 2027 Ceryvyn Therapeutics Ltd Earnings Release
Similar to CYV
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:53 UTC, shares in Ceryvyn Therapeutics are trading at AU$0.01. This share price information is delayed by 15 minutes.
Shares in Ceryvyn Therapeutics last closed at AU$0.01 and the price had moved by -98.17% over the past 365 days. In terms of relative price strength the Ceryvyn Therapeutics share price has underperformed the ASX All Ordinaries Index by -98.08% over the past year.
The overall consensus recommendation for Ceryvyn Therapeutics is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCeryvyn Therapeutics does not currently pay a dividend.
Ceryvyn Therapeutics does not currently pay a dividend.
Ceryvyn Therapeutics does not currently pay a dividend.
To buy shares in Ceryvyn Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.01, shares in Ceryvyn Therapeutics had a market capitalisation of AU$15.05m.
Here are the trading details for Ceryvyn Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CYV
Based on an overall assessment of its quality, value and momentum Ceryvyn Therapeutics is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ceryvyn Therapeutics is AU$0.04. That is 294.17% above the last closing price of AU$0.01.
Analysts covering Ceryvyn Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.00 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ceryvyn Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -98.15%.
As of the last closing price of AU$0.01, shares in Ceryvyn Therapeutics were trading -97.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ceryvyn Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ceryvyn Therapeutics' management team is headed by:
- Jeremy Levin - NEC
- Megan Baldwin - CEO
- Karen Adams - VFN
- Richard Chadwick - OTH
- Mike Gerometta - OTH
- Annette Leahy - OTH
- Ian Leitch - OTH
- Clare Price - OTH
- Judith Robertson - OTH
- Lawrence Gozlan - NID
- Julia Haller - NID
- Michael Sistenich - NID
- Daniel Spiegelman - NID